The Latest Breaking News from FDA

Eli Lilly stock is trading below its key moving averages, but Zepbound just won a new approval. Is LLY stock now a buy?

Postpartum depression affects as many as 1 in 7 women in the U.S., though there are just two treatments approved for it. Experts say the newest could be a game-changer — depending on its price tag.

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

A policy that wasn't rooted solely in science is diminished, but certain barriers to blood donation still remain

Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.

Sage stock plummeted Monday after the FDA approved its drug, Zurzuvae, in postpartum depression, but not major depressive disorder.

Donald Trump's legal team has until 5:00 p.m. to respond to prosecutors' request for a protective order. The FDA has approved the first pill to treat postpartum depression.

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

A new Food and Drug Administration (FDA) recall was just announced for Doritos.

Here’s what we know about the second drug to ever be approved for the post-pregnancy condition

The monoclonal antibody drug prevents the lung infection that puts 58,000 to 80,000 young children in the hospital each year.